ENO1 and non-small cell lung carcinoma: Dai et al. (2017) also reported that combining ENO1 autoantibodies with carcinoembryonic antigen and cytokeratin 19 fragment in a diagnostic panel increased diagnostic sensitivity for non-small cell lung cancer. Another study detected ENO1 autoantibodies at higher frequencies in patients with early stage lung cancer compared to late stage patients (Zhang et al., 2018).